CytoSorbents Corporation (CTSO)

[techxen]

Very good point orangecat. The usage footprint of the cartridge in hospitals is going to expand, which translates into greater adoption, SOC in some areas and increased sales.

I would also venture to say that the current sales split of 70% critical care and 30% cardiac surgery, could even swing the other way where cardiac surgery comprises a greater percentage of the sales than critical care - the market opportunity is that big.

Dr. Deliargyris said it best:

"With the upcoming results from the REMOVE trial evaluating the intraoperative use of CytoSorb in high risk heart valve replacement surgery for infective endocarditis, the recent E.U. approvals for ticagrelor and rivaroxaban removal during cardiac surgery, and the U.S. FDA Breakthrough Designation for ticagrelor removal during cardiopulmonary bypass, the use of CytoSorb in cardiac surgery represents an incredibly exciting area of potential growth that we plan to pursue aggressively."